(S)-N-(4-(1H-pyrazol-4-yl)-2-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxychroman-3-carboxamide

ID: ALA3221809

Chembl Id: CHEMBL3221809

PubChem CID: 90668075

Max Phase: Preclinical

Molecular Formula: C26H30N4O4

Molecular Weight: 462.55

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN1CCCC1)CO2

Standard InChI:  InChI=1S/C26H30N4O4/c1-32-22-5-7-24-19(13-22)12-20(17-34-24)26(31)29-23-6-4-18(21-15-27-28-16-21)14-25(23)33-11-10-30-8-2-3-9-30/h4-7,13-16,20H,2-3,8-12,17H2,1H3,(H,27,28)(H,29,31)/t20-/m0/s1

Standard InChI Key:  KJLWLVXGLALEPO-FQEVSTJZSA-N

Associated Targets(Human)

ROCK2 Tclin Rho-associated protein kinase 2 (6206 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDC42BPA Tchem Serine/threonine-protein kinase MRCK-A (2525 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rock2 Rho-associated protein kinase 2 (125 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 462.55Molecular Weight (Monoisotopic): 462.2267AlogP: 3.75#Rotatable Bonds: 8
Polar Surface Area: 88.71Molecular Species: BASEHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 12.20CX Basic pKa: 8.79CX LogP: 3.17CX LogD: 1.77
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.53Np Likeness Score: -1.39

References

1. Chen YT, Vojkovsky T, Fang X, Pocas JR, Grant W, Handy AMW, Schroter T, LoGrasso P, Bannister TD, Feng Y.  (2011)  Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors,  (1): [10.1039/C0MD00194E]

Source